Amgen (NASDAQ:AMGN) Lowered to “Buy” Rating by Wall Street Zen

Wall Street Zen cut shares of Amgen (NASDAQ:AMGN) from a strong-buy rating to a buy rating in a report issued on Saturday morning.

Several other equities research analysts have also recently weighed in on AMGN. Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 price target on the stock. in a research report on Tuesday, January 20th. Deutsche Bank Aktiengesellschaft boosted their target price on shares of Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a report on Thursday. Wells Fargo & Company increased their price target on shares of Amgen from $300.00 to $325.00 and gave the company an “equal weight” rating in a report on Wednesday, December 10th. BMO Capital Markets boosted their price objective on Amgen from $335.00 to $372.00 and gave the stock an “outperform” rating in a research note on Wednesday, December 3rd. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Amgen in a research report on Monday, December 29th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, ten have assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $351.65.

Amgen Trading Up 4.5%

Shares of AMGN stock opened at $384.20 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.99 and a debt-to-equity ratio of 5.78. The stock has a market capitalization of $206.88 billion, a price-to-earnings ratio of 27.00, a price-to-earnings-growth ratio of 3.90 and a beta of 0.46. Amgen has a 12-month low of $261.43 and a 12-month high of $385.12. The stock’s 50-day moving average price is $334.45 and its 200-day moving average price is $311.49.

Amgen (NASDAQ:AMGN) last announced its quarterly earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a return on equity of 148.37% and a net margin of 20.98%.The company had revenue of $9.87 billion during the quarter, compared to analyst estimates of $9.46 billion. During the same period in the prior year, the company earned $5.31 earnings per share. The firm’s revenue was up 8.6% on a year-over-year basis. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities research analysts predict that Amgen will post 20.62 EPS for the current fiscal year.

Amgen Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be issued a dividend of $2.52 per share. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. Amgen’s dividend payout ratio (DPR) is presently 66.90%.

Insider Buying and Selling at Amgen

In other news, SVP Nancy A. Grygiel sold 3,139 shares of the business’s stock in a transaction on Thursday, November 20th. The shares were sold at an average price of $337.26, for a total transaction of $1,058,659.14. Following the completion of the sale, the senior vice president directly owned 7,225 shares of the company’s stock, valued at approximately $2,436,703.50. The trade was a 30.29% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Rachna Khosla sold 890 shares of the firm’s stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the completion of the transaction, the senior vice president directly owned 7,082 shares in the company, valued at $2,381,251.68. This represents a 11.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 10,908 shares of company stock valued at $3,674,966 in the last quarter. 0.76% of the stock is owned by insiders.

Hedge Funds Weigh In On Amgen

A number of hedge funds have recently added to or reduced their stakes in AMGN. Associated Banc Corp raised its stake in shares of Amgen by 1.0% during the fourth quarter. Associated Banc Corp now owns 23,515 shares of the medical research company’s stock valued at $7,697,000 after acquiring an additional 223 shares in the last quarter. EverSource Wealth Advisors LLC increased its holdings in Amgen by 2.2% during the 4th quarter. EverSource Wealth Advisors LLC now owns 19,555 shares of the medical research company’s stock worth $6,401,000 after purchasing an additional 423 shares during the period. New Millennium Group LLC raised its position in Amgen by 49.1% during the 4th quarter. New Millennium Group LLC now owns 629 shares of the medical research company’s stock valued at $206,000 after purchasing an additional 207 shares in the last quarter. Delta Financial Advisors LLC lifted its holdings in shares of Amgen by 4.1% in the 4th quarter. Delta Financial Advisors LLC now owns 10,301 shares of the medical research company’s stock worth $3,372,000 after buying an additional 407 shares during the period. Finally, Americana Partners LLC grew its position in shares of Amgen by 31.4% during the 4th quarter. Americana Partners LLC now owns 17,085 shares of the medical research company’s stock worth $5,592,000 after buying an additional 4,081 shares in the last quarter. 76.50% of the stock is currently owned by institutional investors.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Argus raised its price target to $400 and reiterated a Buy rating, signaling analyst confidence in Amgen’s outlook and providing fresh positive momentum for the stock. Read More.
• Positive Sentiment: Q4 results beat Street estimates and management’s commentary pushed the shares to a new 12‑month high — the earnings beat and upgraded FY‑2026 guidance underpin the rally. Read More.
• Positive Sentiment: Clinical progress: Amgen advanced xaluritamig into a first‑in‑human Phase 1b trial for hard‑to‑treat Ewing sarcoma — a development that adds long‑term pipeline upside if the program shows activity. Read More.
• Positive Sentiment: Post‑marketing safety study for IMLYGIC in melanoma reached completion — reduces an uncertainty from the label/safety perspective and may support that asset’s commercial outlook. Read More.
• Neutral Sentiment: Guggenheim raised its price target to $347 but kept a Neutral rating; the new PT still implies downside versus the current price, creating mixed signals for investors. Read More.
• Neutral Sentiment: Deutsche Bank moved its target to $295 and maintained a Hold — another measured call that tempers the enthusiasm from Buy-rated upgrades. Read More.
• Neutral Sentiment: Market commentary notes rotation into defensive/health names and institutional buying as contributors to the stock’s move to multi‑month highs — a broader-market technical tailwind rather than company‑specific news. Read More.
• Negative Sentiment: CVS said it will replace Amgen’s and Lilly’s bone‑disease treatments with lower‑cost alternatives on some preferred drug lists starting April 1 — a material commercial headwind for the affected product sales. Read More.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.